Oncolytics Biotech Inc. (ONCY) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
322 11th Avenue SW
Calgary, AB T2R 0C5
Canada
Phone
14036707380
Sector
Healthcare
Industry
Biotechnology
Employees
29
First IPO Date
October 05, 2001
| Name | Title | Pay | Year Born |
| Jared Kelly | Chief Executive Officer & Director | 582,150 | 1986 |
| John Mark Lievonen | Consultant | 18,334 | N/A |
| Allison Hagerman | Chief Technology Officer | 345,170 | 1984 |
| Kirk J. Look | Chief Financial Officer | 575,183 | 1972 |
| Thomas C. Heineman | Chief Medical Officer | 675,471 | 1959 |
| John McAdory | Chief Operating Officer | 0 | 1977 |
| Jon Patton | Director of Investor Relations & Communication | 0 | N/A |
| Andrew Aromando | Chief Business Officer | 0 | 1970 |
| Yujun Wu | VP & Head of Biostatistics | 0 | N/A |
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.